Organogenesis (NASDAQ:ORGO) Shares Down 3.3% – What’s Next?

Organogenesis (NASDAQ:ORGO)’s share price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $5.47 and last traded at $5.4030. 90,679 shares were traded during trading, a decline of 94% from the average session volume of 1,438,622 shares. The stock had previously closed at $5.59.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ORGO shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Organogenesis in a research report on Tuesday. Cantor Fitzgerald increased their price target on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. BTIG Research lifted their price objective on Organogenesis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 20th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Organogenesis Price Performance

The company has a market capitalization of $687.22 million, a P/E ratio of -45.13 and a beta of 1.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The company has a fifty day moving average price of $4.64 and a 200 day moving average price of $4.27.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Organogenesis has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Organogenesis will post -0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ORGO. First Light Asset Management LLC bought a new stake in shares of Organogenesis during the second quarter valued at approximately $24,804,000. Assenagon Asset Management S.A. increased its position in Organogenesis by 748.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock valued at $10,460,000 after acquiring an additional 2,520,941 shares during the period. Driehaus Capital Management LLC acquired a new stake in Organogenesis in the 1st quarter valued at approximately $7,756,000. Invesco Ltd. raised its stake in Organogenesis by 779.7% during the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after acquiring an additional 947,705 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after acquiring an additional 841,618 shares during the period. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.